Ripretinib
INTRIGUE
Deciphera Pharmaceuticals · Phase 3 · Active, not recruiting · Enrollment 453
| Arm | Reported safety |
|---|---|
| Ripretinib 150 mg | grade 3 or 4 treatment-emergent adverse events: 41.3%, primary analysis |
| Sunitinib 50 mg 4/2 | grade 3 or 4 treatment-emergent adverse events: 65.6%, primary analysis |
A count stays a count. This page does not turn a count into a percent.